Hepatic stellate cells suppress NK cell-sustained breast cancer dormancy DOI
Ana Luísa Correia, Joao C. Guimaraes, Priska Auf der Maur

et al.

Nature, Journal Year: 2021, Volume and Issue: 594(7864), P. 566 - 571

Published: June 2, 2021

Language: Английский

Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity DOI Open Access
Filippo Veglia, Emilio Sanseviero, Dmitry I. Gabrilovich

et al.

Nature reviews. Immunology, Journal Year: 2021, Volume and Issue: 21(8), P. 485 - 498

Published: Feb. 1, 2021

Language: Английский

Citations

1271

Mitochondrial metabolism and cancer DOI Creative Commons
Paolo E. Porporato, Nicoletta Filigheddu, José Manuel Bravo‐San Pedro

et al.

Cell Research, Journal Year: 2017, Volume and Issue: 28(3), P. 265 - 280

Published: Dec. 8, 2017

Glycolysis has long been considered as the major metabolic process for energy production and anabolic growth in cancer cells. Although such a view instrumental development of powerful imaging tools that are still used clinics, it is now clear mitochondria play key role oncogenesis. Besides exerting central bioenergetic functions, provide indeed building blocks tumor anabolism, control redox calcium homeostasis, participate transcriptional regulation, govern cell death. Thus, constitute promising targets novel anticancer agents. However, tumors arise, progress, respond to therapy context an intimate crosstalk with host immune system, many immunological functions rely on intact mitochondrial metabolism. Here, we review cell-intrinsic cell-extrinsic mechanisms through which influence all steps oncogenesis, focus therapeutic potential targeting metabolism therapy.

Language: Английский

Citations

1058

NK cells for cancer immunotherapy DOI
Noriko Shimasaki, Amit Jain, Dario Campana

et al.

Nature Reviews Drug Discovery, Journal Year: 2020, Volume and Issue: 19(3), P. 200 - 218

Published: Jan. 6, 2020

Language: Английский

Citations

965

The lung microenvironment: an important regulator of tumour growth and metastasis DOI
Nasser K. Altorki, Geoffrey J. Markowitz, Dingcheng Gao

et al.

Nature reviews. Cancer, Journal Year: 2018, Volume and Issue: 19(1), P. 9 - 31

Published: Dec. 10, 2018

Language: Английский

Citations

908

The updated landscape of tumor microenvironment and drug repurposing DOI Creative Commons

Ming-Zhu Jin,

Weilin Jin

Signal Transduction and Targeted Therapy, Journal Year: 2020, Volume and Issue: 5(1)

Published: Aug. 25, 2020

Abstract Accumulating evidence shows that cellular and acellular components in tumor microenvironment (TME) can reprogram initiation, growth, invasion, metastasis, response to therapies. Cancer research treatment have switched from a cancer-centric model TME-centric one, considering the increasing significance of TME cancer biology. Nonetheless, clinical efficacy therapeutic strategies targeting TME, especially specific cells or pathways remains unsatisfactory. Classifying chemopathological characteristics crosstalk among one another greatly benefit further studies exploring effective treating methods. Herein, we present an updated image with emphasis on hypoxic niche, immune microenvironment, metabolism acidic innervated mechanical microenvironment. We then summarize conventional drugs including aspirin, celecoxib, β-adrenergic antagonist, metformin, statin new antitumor application. These are considered as viable candidates for combination therapy due their activity extensive use practice. also provide our outlook directions potential applications theory. This review depicts comprehensive vivid landscape biology treatment.

Language: Английский

Citations

893

Natural killer cells and other innate lymphoid cells in cancer DOI
Laura Chiossone, Pierre‐Yves Dumas, Margaux Vienne

et al.

Nature reviews. Immunology, Journal Year: 2018, Volume and Issue: 18(11), P. 671 - 688

Published: Sept. 12, 2018

Language: Английский

Citations

864

Nanomaterials for cancer therapy: current progress and perspectives DOI Creative Commons
Zhe Cheng, Maoyu Li,

Raja Dey

et al.

Journal of Hematology & Oncology, Journal Year: 2021, Volume and Issue: 14(1)

Published: May 31, 2021

Abstract Cancer is a disease with complex pathological process. Current chemotherapy faces problems such as lack of specificity, cytotoxicity, induction multi-drug resistance and stem-like cells growth. Nanomaterials are materials in the nanorange 1–100 nm which possess unique optical, magnetic, electrical properties. used cancer therapy can be classified into several main categories. Targeting cells, tumor microenvironment, immune system, these nanomaterials have been modified for wide range therapies to overcome toxicity enhance drug capacity well bioavailability. Although number studies has increasing, approved nano-drugs not increased much over years. To better improve clinical translation, further research needed targeted delivery by nano-carriers reduce toxicity, permeability retention effects, minimize shielding effect protein corona. This review summarizes novel fabricated use, discusses current limitations obstacles that hinder translation from provides suggestions more efficient adoption therapy.

Language: Английский

Citations

846

Rhabdomyosarcoma DOI
Stephen X. Skapek, Andrea Ferrari, Abha A. Gupta

et al.

Nature Reviews Disease Primers, Journal Year: 2019, Volume and Issue: 5(1)

Published: Jan. 7, 2019

Language: Английский

Citations

678

NK cell-based cancer immunotherapy: from basic biology to clinical development DOI Creative Commons
Sizhe Liu, Vasiliy Galat, Yekaterina Galat

et al.

Journal of Hematology & Oncology, Journal Year: 2021, Volume and Issue: 14(1)

Published: Jan. 6, 2021

Abstract Natural killer (NK) cell is a specialized immune effector type that plays critical role in activation against abnormal cells. Different from events required for T activation, NK governed by the interaction of receptors with target cells, independent antigen processing and presentation. Due to relatively unsophisticated cues has gained significant attention field cancer immunotherapy. Many efforts are emerging developing engineering cell-based In this review, we provide our current understandings biology, ongoing pre-clinical clinical development therapies discuss progress, challenges, future perspectives.

Language: Английский

Citations

495

The hallmarks of successful anticancer immunotherapy DOI Open Access
Lorenzo Galluzzi, Timothy A. Chan, Guido Kroemer

et al.

Science Translational Medicine, Journal Year: 2018, Volume and Issue: 10(459)

Published: Sept. 19, 2018

Various features of the tumor and immune system influence success immunotherapy.

Language: Английский

Citations

493